HR-positive HER2-negative breast cancer

You have access
Efficacy and Safety of Oral 5-FU Derivatives After Progression of HR⁺/HER2⁻ Metastatic Breast Cancer on CDK4/6 Inhibitor
YUMIKO KOI, WAKAKO TAJIRI, JUNJI KAWASAKI, SAYURI AKIYOSHI, HIDEKI IJICHI, YOSHIAKI NAKAMURA, CHINAMI KOGA and ERIKO TOKUNAGA

Anticancer Research December 2025, 45 (12) 5609-5618; DOI: https://doi.org/10.21873/anticanres.17895